PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28391030-2	2017	In the present study we investigated the influence of the anti-diabetic drug metformin on the cytotoxic effects of EGFR targeted therapy and chemotherapy in 7 non-small cell lung cancer (NSCLC) cell lines and a cohort of lung cancer patients with/without T2D.	Metformin	77-86	epidermal growth factor receptor	Homo sapiens	115-119	
28391030-4	2017	EGFR downstream signaling evaluation further demonstrated that metformin, at its IC50 value, modified apoptosis caused in erlotinib or chemotherapeutic agent-treated cells via AKT activation and the inhibition of caspase 3 and PARP cleavages.	Metformin	63-72	epidermal growth factor receptor	Homo sapiens	0-4	
28391030-8	2017	Consequently, the application of metformin for T2D NSCLC patients receiving chemo or EGFR targeted therapy should be considered with caution.	Metformin	33-42	epidermal growth factor receptor	Homo sapiens	85-89